%0 Journal Article
%T Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
%A Aldo V Giordano
%A Alessandro Parisi
%A Alessio Cortellini
%A Antonella Dal Mas
%A Antonio Marchetti
%A Antonio Russo
%A Carla DĄŻOrazio
%A Corrado Ficorella
%A Fiamma Buttitta
%A Giuseppe Calvisi
%A Katia Cannita
%A Lara Felicioni
%A Olga Venditti
%A Paola Lanfiuti Baldi
%A Roberto Vicentini
%A Vincenzo Vicentini
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S194745
%X Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting interesting results in terms of received dose intensities (rDIs) and safety
%K metastatic colorectal cancer
%K intensive chemotherapy regimen
%K bevacizumab
%K clinical practice
%K 5-fluorouracil infusion
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438145/